Pathos AI, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC (NCT06785636) | Pathos AI, Inc. | 2025-02-07 |
Track Pathos AI, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.